Diplomat Specialty Pharmacy earns recognition from MichBio; spotlighted in Pure Michigan video
FLINT, Mich. — Diplomat Specialty Pharmacy was recognized by MichBio, a biosciences industry trade association and the official Michigan affiliate of the Biotechnology Industry Organization.
Diplomat received the Good to Great award from the organization, which recognized "as a company whose business concept, entrepreneurialism, leadership, work ethic and products have melded in just the right way to produce a leap forward in the past year," MichBio president and CEO Stephen Rapundalo said. "MichBio views Diplomat as a strong and visible indicator that our industry is thriving here in Michigan and that the outlook for the state’s biosciences sector seems positive. Success breeds success, and Diplomat’s tremendous strides in commercialization will serve as a beacon for others."
Diplomat president and CEO Phil Hagerman said this achievement was made possible by the company’s staff and its healthcare partners.
In related news, Diplomat also was featured in a video produced by the Michigan Economic Development Center and the city of Flint, called Pure Michigan, which illustrated how Flint is transforming itself into a leading center of commerce and provide a glimpse of the future Michigan, Diplomat said. The video highlights the strides and development in the city, which was made possible by Diplomat, as well as General Motors.
To view the video, click here.
UnitedHealth Group’s DPCA underscores Not Me program during National Diabetes Month
MINNETONKA, Minn. — The UnitedHealth Group’s Diabetes Prevention and Control Alliance is emphasizing its Not Me program — an employer- and community-based initiative aimed at combating the epidemic of Type 2 diabetes, prediabetes and obesity — in line with National Diabetes Month.
The program encourages Americans to get tested for blood-glucose, cholesterol and blood-pressure levels. These indicators, along with such factors as age, family history and lifestyle habits, may pose as warning signs for those at risk of prediabetes, Type 2 diabetes or obesity, DPCA said.
“There is power in information, and knowing your numbers is the first, all-important step in learning whether you might be at risk for prediabetes or diabetes and saying ‘Not Me’ to these conditions,” DPCA EVP and chief clinical officer Deneen Vojta said. “UnitedHealth Group is helping people prevent and control diabetes so they can focus on leading healthier and more productive lives.”
Salix to acquire Oceana Therapeutics
RALEIGH, N.C. — Salix Pharmaceuticals has entered a definitive agreement to acquire all outstanding stock of a provider of gastroenterology and urology therapeutics.
Salix said its acquisition of Oceana Therapeutics’ outstanding stock is valued at $300 million in cash. The transaction is subject to customary conditions to closing (including U.S. antitrust approval) and is expected to be completed in December.
"The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix’s base business and provides immediate added revenue," Salix president and CEO Carolyn Logan said. "Oceana markets two differentiated products — Solesta, a first-in-class, biocompatible tissue bulking agent for the treatment of fecal incontinence — and Deflux, the only [Food and Drug Administration]-approved alternative to major ureteral reimplantation surgery for the treatment of vesicoureteral reflux."